Advancing the Vaccine Law Dialogue

Pre-conference: September 13 Washington, D.C.

Kevin Outterson

Kevin Outterson 

Professor of Law, Boston University School of Law

Professor Outterson teaches health law and corporate law at Boston University, where he co-directs the Health Law Program, currently ranked #5 in the country by US News and World Report. He is the executive director of Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global partnership hosted at BU Law that is focused on supporting developers of promising new antibiotics, diagnostics, and vaccines that tackle the threat of untreatable bacterial infections. CARB-X has built the world’s largest and most innovative antibacterial pipeline, with $480 million in grant funding from three governments (US, UK, and Germany) and two foundations (Wellcome Trust and the Bill & Melinda Gates Foundation). He also leads the Social Innovation on Drug Resistance program at Boston University.

His research focuses on the organization and finance of the health sector. Areas of specialization include global pharmaceutical markets, particularly antibiotics and other antimicrobials that can degrade in usefulness over time through resistance. He participated in a grant from the European Union’s Innovative Medicines Initiative to study business models and incentives for antibiotic development. He leads an interdisciplinary project on the legal ecology of antimicrobial resistance, funded in part by the Robert Wood Johnson Foundation program on public health law. He is an associate fellow at the Royal Institute of International Affairs at Chatham House, London, where he works on global solutions to antibiotic resistance, and an appointed member of the Antimicrobial Resistance Working Group at the Centers for Disease Control.